Risk Factors for Rebleeding after Emergency Endoscopic Treatment of Dieulafoy Lesion

Table 2

Comparison of baseline clinical characteristics among pure injection, nonpure injection, and combination therapy.

Characteristic	Pure injection (n = 31)	Nonpure injection (n = 47)	Combination therapy (n = 55)	value
Age, years, mean ± SD	56.52 ± 3.29	55 ± 2.62	56.69 ± 1.95	0.865
Gender, male	23 (74.19%)	42 (89.36%)	50 (90.91%)	0.096
DL location, stomach	15 (48.39%)	35 (74.47%)	40 (72.73%)	0.032
Forrest classification, FI	14 (45.16%)	20 (42.55%)	30 (54.55%)	0.449
Rockall score	3.84 ± 0.19	3.91 ± 0.16	3.76 ± 0.12	0.745
AIMS65 score	0.97 ± 0.16	1.02 ± 0.15	1.05 ± 0.12	0.921
Blatchford score	9.03 ± 0.51	9.28 ± 0.46	8.95 ± 0.36	0.841
Alcohol	3 (9.68%)	10 (21.28%)	18 (32.73%)	0.048
Smoking	9 (29.03%)	18 (38.3%)	15 (27.27%)	0.461
History of peptic ulcer	2 (6.45%)	9 (19.15%)	8 (14.55%)	0.274
Hypertension	6 (19.35%)	11 (23.4%)	5 (9.1%)	0.136
Diabetes mellitus	0	3 (6.38%)	3 (5.45%)	0.498
Mean systolic blood pressure, mean ± SD	78.55 ± 2.09	80.74 ± 2.14	83.13 ± 1.9	0.324
Heart rate, mean ± SD	89.39 ± 3.07	88.19 ± 2.91	81.75 ± 2.43	0.086
Hemoglobin, mean ± SD	77.16 ± 3.91	79.49 ± 3.36	78.29 ± 3.32	0.91
WBC (10^9/L), mean ± SD	8.67 ± 0.82	9.23 ± 0.71	8.16 ± 0.55	0.488
PLT (10^9/L), mean ± SD	182.94 ± 12.44	173.84 ± 14.52	163.215.59	0.672
BUN (mmol/L), mean ± SD	10.09 ± 1.29	9.3 ± 0.64	10.07 ± 1.07	0.814
Cr (umol/L), mean ± SD	102.39 ± 26.14	77.68 ± 3.51	82.11 ± 3.21	0.517
Albumin (g/L), mean ± SD	30.77 ± 1.03	32.28 ± 0.98	30.31 ± 0.79	0.261
PT (s), mean ± SD	12.1 ± 0.3	12.58 ± 0.33	14.37 ± 1.82	0.434
APTT (s), mean ± SD	30.16 ± 1.09	30.94 ± 1.82	30.16 ± 1.49	0.924
INR, mean ± SD	1.06 ± 0.03	1.11 ± 0.03	1.11 ± 0.03	0.447
Operation	4 (12.9%)	1 (2.13%)	0	0.005
Mortality	1(3.23%)	1(2.13%)	1(1.82%)	1